Amlodipine and valsartan: Calcium channel blockers/angiotensin II receptor blockers combination for hypertenion

Therapy

Volumn 4, Issue 1, 2007, Pages 31-40

  Kjeldsen, Sverre E ^a   Aksnes, Tonje A ^a   de la Sierra, Alex ^b   Ruilope, Luis M ^c  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b HOSPITAL CLÍNIC   (Spain)

^c Hypertension Unit   (Spain)

Author keywords

Amlodipine; Calcium channel blockers; Hypertension; Valsartan

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS VALSARTAN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; LOSARTAN; NATEGLINIDE; PERINDOPRIL; PLACEBO; RAMIPRIL; SODIUM; VALSARTAN;

ANKLE EDEMA; ARTICLE; BEHAVIOR CHANGE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIURESIS; DRUG EFFICACY; DRUG POTENTIATION; DRUG WITHDRAWAL; HIGH RISK PATIENT; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE; MEDICAL DECISION MAKING; MONOTHERAPY; MORBIDITY; MORTALITY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; RISK REDUCTION; SODIUM EXCRETION; STROKE; SYSTOLIC BLOOD PRESSURE; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VASODILATATION;

EID: 33847271110     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/14750708.4.1.31     Document Type: Article

References (58)

1. Leal J, Luengo-Fernandez R, Gray A, Petersen S, Rayner M: Economic burden of cardiovascular diseases in the enlarged European Union. Eur. Heart J. 27, 1610-1619 (2006).
2. ESH/ESC Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 21, 1011-1053 (2003).
3. Wolf-Maier K, Cooper RS, Kramer H et al.: Hypertension treatment and control in five European countries. Canada, and the United States. Hypertension 43, 10-17 (2004).
4. Wolf-Maier K, Cooper RS, Banegas JR et al.: Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 289, 2363-2369 (2003).
5. Kearney PM, Whelton M, Reynolds K et al.: Global burden of hypertension: analysis of worldwide data. Lancet 365, 217-223 (2005).
6. Kaplan NM, Opie LH: Controversies in hypertension. Lancet 367, 168-176 (2006).
7. Antikainen RL, Moltchanov VA, Chukwuma C Sr et al.: Trends in the prevalence, awareness, treatment and control of hypertension: the WHO MONICA Project. Eur. J. Cardiovasc. Prev. Rehabil. 13, 13-29 (2006).
8. Chobanian AV, Bakris GL, Black HR et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289, 2560-2572 (2003).
9. Lewington S, Clarke R. Qizilbash N, Peto R, Collins R: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360, 1903-1913 (2002).
10. Hansson L, Lloyd A, Anderson P, Kopp Z: Excess morbidity and cost of failure to achieve targets for blood pressure control in Europe. Blood Press. 11, 35-45 (2002).
11. Elmer PJ, Obarzanek E, Vollmer WM et al.: Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann. Intern. Med. 144, 485-495 (2006).
12. Chobanian AV: Control of hypertension - an important national priority. N Engl. J. Med. 345, 534-535 (2001).
13. Munger MA: Critical overview of antihypertensive therapies: what is preventing us from getting there? Am. J. Manag. Care 6(4 Suppl.), S211-S221 (2000).
14. Phillips LS, Branch WT, Cook CB et al.: Clinical inertia. Ann. Intern. Med. 135, 825-834 (2001).
15. Berlowitz DR, Ash AS, Hickey EC etal.: Inadequate management of blood pressure in a hypertensive population. N. Engl. J. Med. 339, 1957-1963 (1998).
16. Menard J: Critical assessment of combination therapy development. Blood Press. 1(Suppl.), 5-9 (1993).
17. Burnier M: Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am. J. Hypertens. 19, 1190-1196 (2006).
18. Weber MA, Julius S, Kjeldsen SE et al.: Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 363, 2049-2051 (2004).
19. Staessen JA, Thijisq L, Fagard R et al.: Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J. Hypertens. 22, 847-857 (2004).
20. Basile JN, Chrysant S: The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy. J. Hum. Hypertens. 20, 169-175 (2006).
21. Milani RV: Reaching for aggressive blood pressure goals: role of angiotensin receptor blockade in combination therapy. Am. J. Manag. Care 11(7 Suppl.), S220-S227 (2005).
22. Messerli F: A rationale for combination therapy. In: Clinician's Manual on Combination Therapy and Hypertension. Messerli F (Ed.). Science Press, London, UK (2003).
23. Andreadis EA, Tsourous GI, Marakomichelakis GE et al.: High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension. J. Hum. Hypertens. 19, 491-496 (2005).
24. Frishman WH, Burris JF, Mroczek WJ et al.: First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J. Clin. Pharmacol. 35, 182-188 (1995).
25. Mason JM, Dickinson HO, Nicolson DJ et al.: The diabetogenic potential of thiazide-type diuretic and β-blocker combinations in patients with hypertension. J. Hypertens. 23, 1777-1781 (2005).
26. Dahlof B, Devereux RB, Kjeldsen SE et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359, 995-1003 (2002).
27. Dahlof B. Sever PS, Poulter NR et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a Multicenter randomised controlled trial. Lancet 366, 895-906 (2005).
28. National Collaborating Centre for Chronic Conditions: Hypertension: Management of Hypertension in Adults in Primary Care: Partial Update. London: Royal College of Physicians, London, UK (2006).
29. Kjeldsen SE, Julius S, Mancia G et al.: Effects of valsartan compared to amlodipine on preventing Type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J. Hypertens. 24, 1405-1412 (2006).
30. Chrysant SG: Fixed low-dose drug combination for the treatment of hypertension. Arch. Fam. Med. 7, 370-376 (1998).
31. Cappuccio FP, Markandu ND, Singer DR, MacGregor GA: Amlodipine and lisinopril in combination for the treatment of essential hypertension: efficacy and predictors of response. J. Hypertens. 11, 839-847 (1993).
32. Jamerson KA, Nwose O, Jean-Louis L et al.: Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am. J. Hypertens. 17, 495-501 (2004).
33. Morgan T, Anderson A, Hopper J: Enalapril and nifedipine in essential hypertension; synergism of the hypotensive effects in combination. Clin. Exp. Hypertens. 10, 779-789 (1988).
34. ter Wee PM, Epstein M: Angiotensin-converting enzyme inhibitors and progression of nondiabetic chronic renal disease. Arch. Intern. Med. 153, 1749-1759 (1993).
35. ter Wee PM, De Micheli AG, Epstein M: Effects of calcium antagonists on renal hemodynamics and progression of nondiabetic chronic renal disease. Arch. Intern. Med. 154, 1185-1202 (1994).
36. Bakris GL, Barnhill BW, Sadier R: Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney. Int. 41, 912-919 (1992).
37. DREAM Trial Investigators, Bosch J, Yusuf S et al.: Effect of ramipril on the incidence of diabetes. N. Engl. J. Med. 355, 1551-1562 (2006).
38. Semple PF: Putative mechanisms of cough after treatment with angiotensin converting enzyme inhibitors. J. Hypertens. 13(Suppl.), S17-S21 (1995).
39. Quan A, Chavanu K, Merkel J: A review of the efficacy of fixed-dose combinations olmesartan medoxomil/hydrochlorothiazide and amlodipine besylate/benazepril in factorial design studies. Am. J. Cardiovasc. Drugs 6, 103-113 (2006).
40. Sica DA: Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 62, 443-462 (2002).
41. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M: Effects of amlodipine and valsartan on vascular damage and ambulatory blood pressure in untreated hypertensive patients. J. Hum. Hypertens. 20, 787-794 (2006).
42. Ishimitsu T. Kobayashi T, Honda T et al.: Protective effects of an angiotensin II receptor blocker and a long-acting calcium channel blocker against cardiovascular organ injuries in hypertensive patients. Hypertens. Res. 28, 351-359 (2005).
43. Julius S, Kjeldsen SE, Weber M et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363, 2022-2031 (2004).
44. Schmieder RE: Mechanisms for the clinical benefits of angiotensin II receptor blockers. Am. J. Hypertens. 18(5 Pt 1), 720-730 (2005).
45. Maggioni AP, Latini R: The angiotensin-receptor blockers: from antihypertensives to cardiovascular all-round medications in 10 years? Blood Press. 11, 328-338 (2002).
46. Weber MA: The angiotensin II receptor blockers: opportunities across the spectrum of cardiovascular disease. Rev. Cardiovasc. Med. 3, 183-191 (2002).
47. Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 345, 1667-1675 (2001).
48. Viberti G, Wheeldon NM: Microalbuminuria reduction with valsartan in patients with Type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 106, 672-678 (2002).
49. Wogen J, Kreilick CA, Livornese RC, Yokoyama K, Frech F: Patient adherence with amlodipine. lisinopril, or valsartan therapy in a usual-care setting. J. Manag. Care Pharm. 9, 424-429 (2003).
50. Clavijo GA, de C, IV, Weart CW: Amlodipine: a new calcium antagonist. Am. J. Hosp. Pharm. 51, 59-68 (1994).
51. Neaton JD, Grimm RH Jr, Prineas RJ et al.: Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 270, 713-724 (1993).
52. ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288, 2981-2997 (2002).
53. Messerli FH: Evolution of calcium antagonists: past, present, and future. Clin. Cardiol. 26(2 Suppl. 2). II12-II16 (2003).
54. Pascual J: Hypertension control in the elderly with amlodipine. Curr. Med. Res. Opin. 16, 33-36 (2000).
55. Cocco G, Alfiero R: A double-blind dose-response study of amlodipine in patients with stable angina pectoris. Eur. Heart J. 12, 169-174 (1991).
56. Poldermans D, Gamboa R. Fomina I et al.: Comparative safety and blood pressure (BP)-lowering efficacy of a combination of amlodipine + valsartan and lisinopril + hydrochlorothiazide in patients with stage 2 hypertension. J. Clin. Hypertens. 8(5 Suppl. A), A96 (2006).
57. Fogari R, Perrone T, Musca F et al.: Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J. Hypertens. 24(Suppl. 4). S34 (2006).
58. Wald NJ, Law MR: A strategy to reduce cardiovascular disease by more than 80%. BMJ 326, 1419 (2003).